Incyte (INCY) Payables (2010 - 2026)
Incyte (INCY) posted Payables of $228.6 million for Q1 2026, up 8.9% on a QoQ basis from $209.9 million in Q4 2025, and up 16.92% year-over-year from $195.5 million in Q1 2025.
Incyte (INCY) Payables (2010 - 2026) Analysis & Trends
Incyte's Payables history runs 17 years deep, the most recent figure standing at $228.6 million for Q1 2026.
- Quarterly Payables rose 16.92% year-over-year to $228.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $228.6 million (up 16.92% YoY) and the FY2025 annual result came in at $209.9 million, up 6.32% from the prior year.
- Payables was $228.6 million for Q1 2026 at Incyte, up from $209.9 million in the prior quarter.
- Across five years, Payables topped out at $277.5 million in Q4 2022 and bottomed at $55.6 million in Q1 2023.
- A 5-year average of $175.5 million and a median of $171.9 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables tumbled 63.53% — and 2024, when it jumped 195.22%.
- Incyte's Payables stood at $277.5 million in 2022, then slumped by 60.51% to $109.6 million in 2023, then jumped by 80.17% to $197.5 million in 2024, then advanced by 6.32% to $209.9 million in 2025, then grew by 8.9% to $228.6 million in 2026.
- Business Quant data shows INCY's Payables at $228.6 million in Q1 2026, $209.9 million in Q4 2025, and $171.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 8.69 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 80.54 Mn |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn | 228.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 228.62 Mn |
| Dec 31, 2025 | 209.94 Mn |
| Sep 30, 2025 | 171.93 Mn |
| Jun 30, 2025 | 241.09 Mn |
| Mar 31, 2025 | 195.54 Mn |
| Dec 31, 2024 | 197.47 Mn |
| Sep 30, 2024 | 178.71 Mn |
| Jun 30, 2024 | 148.17 Mn |
| Mar 31, 2024 | 164.24 Mn |
| Dec 31, 2023 | 109.60 Mn |
| Sep 30, 2023 | 139.41 Mn |
| Jun 30, 2023 | 155.54 Mn |
| Mar 31, 2023 | 55.63 Mn |
| Dec 31, 2022 | 277.55 Mn |
| Sep 30, 2022 | 163.18 Mn |
| Jun 30, 2022 | 194.77 Mn |
| Mar 31, 2022 | 152.55 Mn |
| Dec 31, 2021 | 172.11 Mn |
| Sep 30, 2021 | 114.51 Mn |
| Jun 30, 2021 | 122.10 Mn |